Updated on 30 July 2013
Mr Olivier Brandicourt will lead the transition from the current emerging markets organization to the regional structure that will be established for each of the three business segments. Furthermore, Mr Douglas Lankler, currently chief compliance and risk officer, will become general counsel, and Ms Rady Johnson, currently senior vice president and associate general counsel, will become chief compliance and risk officer.
Mr Ian Read, chairman and chief executive officer, said that, "This represents the next steps in Pfizer's journey to further revitalize our innovative core, enhance the value of our consumer and off-patent established brands and maximize the use of our capital to create value for Pfizer and our shareholders. Through this evolution, we will enable greater independence and focus for the innovative and value businesses."